Starpharma Completes $32M Entitlement Offer
Key points
- Successful completion of $32M Entitlement Offer
- 99% take-up rate from existing shareholders
- Proceeds to fund oncology research and development
Full summary
Starpharma Holdings Ltd announced the successful completion of its fully underwritten 1 for 7.5 renounceable pro rata entitlement offer, raising $32 million before costs. The offer, which closed on 4 August 2026, saw a 99% take-up rate from existing shareholders, including $5.4 million under the Oversubscription Facility. The underwriter, Canaccord Genuity, will cover any shortfall. The new shares will be allotted on 11 August 2026, ranking equally with existing shares. The net proceeds will be distributed on 14 August 2026. The funds will support the DEP® HER2-Lutetium program and other oncology assets, building on Starpharma's recent momentum.
Summary generated by a large language model. Please interpret with care.